HIPAA Alert: Potential Data Breach Learn More

Search
Close this search box.

Timothy H. Chen, MD

Board Certifications: Radiation Oncology

Languages: English, Mandarin and Taiwanese

Locations: Hackensack, NJ

Timothy H. Chen is medical director of the Stereotactic Radiosurgery Program Department of Radiation Oncology with Capital Health. He practices out of the Regional Cancer Care Associates Hackensack location. Prior to that he was attending radiation oncologist at Saint Clare’s Hospital; and vice chairman of the Department of Radiation Oncology, Morristown Medical Center. He received his Master of Health Care management from Harvard University.

Education

Medical Education

  • Doctor of Medicine, Santiago University of Technology School of Medicine
  • Bachelor of Science in Medical Technology, Taipei Medical College School of Medical Technology

Residency

  • Chief resident/two terms, New York and Presbyterian Hospital Weill Cornell Medical College, Department of Radiation Oncology
  • Resident, SUNY Health Science Center at Syracuse, Department of Radiation Oncology, Upstate Medical Center

fellowship

Visiting Fellow/Pediatric Radiation Oncology, Joint Center for Radiation Therapy, Harvard Medical School, Boston Children’s Hospital/Department of Radiation oncology

board Certification

American Board of Radiology, 1999

Awards and honors

Awards and honors

Professional Memberships

  • American Brachytherapy Society, 2001 – present
  • American Society for Therapeutic Radiology and Oncology, 1995 – present
  • American College of Radiology, 1995 – present; and American College of Radiation Oncology, 1995 – present

we are here for you

For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.

Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.